Should you buy Organon & (OGN)?
Updated
Organon carries an attractive valuation with a forward P/E of 3.7x and a PEG of 0.06, supported by strong free cash flow generation at 215% of net income, though revenue is declining 4% and the risk/reward is currently unfavorable with the price already above its resistance-based take-profit target.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Organon derives 74% of revenue from outside the United States and 59% from established brands, creating meaningful concentration risk that limits pricing power and exposes earnings to currency and generic-competition headwinds. Bear case | Concentration risk diminishes if revenue from non-Established-Brands segments grows to represent more than 45% of sales within 12 months. | →Stable |
| CounterGeographic diversification can be a stabilizer in domestic downturns, and established brand revenues may be more predictable than new product lines. | ||
With a forward P/E of 3.7x and a PEG ratio of 0.06, Organon trades at a substantial discount relative to its earnings power, suggesting the market has priced in significant pessimism that may be excessive. Valuation breakdown | The stock re-rates toward a forward P/E above 6x over 12 months as earnings stability is demonstrated. | →Stable |
| CounterThe deep discount may reflect structurally declining revenue and a business with two earnings misses in the last four quarters, making multiple expansion unlikely without a growth catalyst. | ||
Free cash flow conversion of 215% relative to net income reflects high-quality earnings and a business generating substantial cash despite topline pressures, supporting the dividend and debt service. Quality breakdown | Free cash flow remains above 150% of net income over the next four reported quarters, validating cash generation quality. | →Stable |
| CounterRevenue declining at 4% annually could eventually compress cash flow if cost cuts have already been exhausted, making the high conversion ratio unsustainable. | ||
Organon derives 74% of revenue from outside the United States and 59% from established brands, creating meaningful concentration risk that limits pricing power and exposes earnings to currency and generic-competition headwinds.
→Stable- Expectation
- Concentration risk diminishes if revenue from non-Established-Brands segments grows to represent more than 45% of sales within 12 months.
CounterGeographic diversification can be a stabilizer in domestic downturns, and established brand revenues may be more predictable than new product lines.
With a forward P/E of 3.7x and a PEG ratio of 0.06, Organon trades at a substantial discount relative to its earnings power, suggesting the market has priced in significant pessimism that may be excessive.
→Stable- Expectation
- The stock re-rates toward a forward P/E above 6x over 12 months as earnings stability is demonstrated.
CounterThe deep discount may reflect structurally declining revenue and a business with two earnings misses in the last four quarters, making multiple expansion unlikely without a growth catalyst.
Free cash flow conversion of 215% relative to net income reflects high-quality earnings and a business generating substantial cash despite topline pressures, supporting the dividend and debt service.
→Stable- Expectation
- Free cash flow remains above 150% of net income over the next four reported quarters, validating cash generation quality.
CounterRevenue declining at 4% annually could eventually compress cash flow if cost cuts have already been exhausted, making the high conversion ratio unsustainable.
▸ Show 1 more pillar▾ Show fewer
Organon has missed earnings estimates in 2 of the last 4 quarters with an average surprise of -3.8%, signaling that management guidance and analyst models may not fully reflect the pressure on the business.
→Stable- Expectation
- Earnings surprise turns positive in at least 3 of the next 4 quarters, indicating guidance has been reset to a beatable level.
CounterTwo of the four recent quarters were beats, suggesting the miss pattern is not yet a confirmed trend, and the Q3 2025 beat of +8.5% shows the business can outperform when conditions allow.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1With a forward P/E of 3.7x and a PEG ratio of 0.06, Organon trades at a substantial discount relative to its earnings power, suggesting the market has priced in significant pessimism that may be excessive.
Trip ifForward P/E falls below 3x for 2 consecutive quarters, signaling further earnings deterioration beyond current estimates.
- P2Free cash flow conversion of 215% relative to net income reflects high-quality earnings and a business generating substantial cash despite topline pressures, supporting the dividend and debt service.
Trip ifFree cash flow conversion falls below 100% of net income for 2 consecutive quarters.
- P3Organon derives 74% of revenue from outside the United States and 59% from established brands, creating meaningful concentration risk that limits pricing power and exposes earnings to currency and generic-competition headwinds.
Trip ifRevenue from outside the United States rises above 78% of total sales, indicating concentration risk is increasing rather than decreasing.
- P4Organon has missed earnings estimates in 2 of the last 4 quarters with an average surprise of -3.8%, signaling that management guidance and analyst models may not fully reflect the pressure on the business.
Trip ifEPS surprise falls below -10% in at least 3 of the next 4 quarters, confirming a structural guidance credibility problem.
How the engine reached this verdict
TrendMatrix's engine output for Organon & Co. (OGN) is SELL_IF_HOLDING with high conviction, score 5.5/10 at $13.48. The F-path SELL output reflects an overall score of 4.0 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of -1.94 is supplementary context, not the trigger.
The engine's exit framework anchors to a tactical sell band near $13.48, with structural invalidation at $13.38. The asymmetric R:R against a reversal hypothesis is -2.50 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bull side: Attractive valuation. On the bear side: Concentration risk — Geographic: outside United States (74.0%); Concentration risk — Product: Established Brands (59.0%); Analyst target reached - limited upside remaining. Active engine warnings: V8: Target reached (-29.1% upside), V9 Gate Failed: ASYMMETRY:-1.9=NEGATIVE.
The dominant failed gate is reward-to-risk (NEGATIVE). SELL flips back toward HOLD if reward-to-risk recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is MOMENTUM:5.3>=4.5.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates OGN — 10-dimension breakdown →
Bull case
- ▸Attractive valuation
Bear case
- ▸Concentration risk — Geographic: outside United States (74.0%)
- ▸Concentration risk — Product: Established Brands (59.0%)
- ▸Analyst target reached - limited upside remaining